Pharmafile Logo

GE Healthcare

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

Nanobiotix signs €40m deal with the EIB

loan to fund innovative nanomedicine platform

Celgene building

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates

Roche Basel Switzerland

Roche’s Tamiflu successor hits the mark in complicated flu

Baloxavir marboxil met its primary objective and cut flu-related complications

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

SWITCHED ONcology Patient Experience Focus Group Full Discussion

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. In...

Havas Lynx

SWITCHED ONcology Patient Experience Focus Group Highlights

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. "We...

Havas Lynx

- PMLiVE

NHS England says yes to Roche’s Hemlibra

But stalls on funding for Actelion's Uptravi

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links